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Summary This paper describes the epidemiology of Hodgkin's disease occurring in parts of the United
Kingdom between 1984 and 1986. The cases were carefully diagnosed and the data rigorously cross-checked as
part of the larger Leukaemia Research Fund Data Collection Survey of all lymphoid and haematogenous
malignancies. The age-specific rates show the lack of an older adult second peak. Spatial variation is examined
in some detail. At county and district levels there is little heterogeneity in the distribution of cases. However,
at the electoral ward level there were real differences for the younger age group (0-34).
In contrast to other haematogenous malignancies the his-
tological classification of Hodgkin's disease (HD) and its
subtypes has remained in use since Lukes and Butler (1966)
defined the Rye modification of their original scheme. Recent
studies at the cellular level confirm that HD is a lymphoid
neoplasm and investigations at the molecular level suggest
that different immunoglobulin gene rearrangements may be
linked to the subclasses of HD (Stein et al., 1986; Griesser et
al., 1987). The origin of the Reed-Sternberg cell, which dis-
tinguishes HD from other lymphomas, remains a controver-
sial issue (Bucsky, 1987, Drexler & Leber, 1988) and
cytogenetic studies have so far failed to characterise further
this tumour (Kristoffersson et al., 1987; Cabanillas, 1988).
Currently no consistent available evidence suggests that the
basic Rye classification should be modified.
Descriptive statistics for HD in the United Kingdom are
published by the Office of Population Censuses and Surveys
(OPCS, 1978-1988) based on regional cancer registrations.
These data are unsatisfactory for investigating either recent
trends or geographical differences at other than a regional
level. Perhaps of greater importance are the doubts cast on
the reliability of leukaemia/lymphoma registrations by the
national system, particularly with regard to diagnostic
accuracy (Barnes et al., 1986). Delays in registration and use
of unconfirmed diagnoses make cancer registry data of ques-
tionable value for this range of diseases (Bowie, 1987; Alex-
ander et al., 1989a).
To overcome some of these difficulties and account for the
criticisms cited above, a specialist registry of leukaemias,
lymphomas and allied disorders was set up in 1984. Initially
the aim of the survey was to obtain optimal ascertainment
with rapid registration across the entire study area. This
comprised a large area of the UK with a population of
approximately 16 million. The number of regions varied by
year, resulting in changes of the base line population. For all
disease groups, modern classification systems of disease sub-
types were incorporated, making use, for example, of
immunophenotyping techniques. Once the registrational pro-
cedures were in operation the registry aimed to provide
reliable data for a wide variety of epidemiological analyses.
The current paper focuses on HD with the presentation of
descriptive results on the age-sex distribution of disease
subtypes and also the geographical pattern.
Methods
The Leukaemia Research Fund data collection survey
The data collection survey (DCS) aims to use medical diag-
nosticians as the focal point of notifications for a specialist
registry of haematopoetic malignancies and related condi-
tions. Registrations are sent direct to the Leukaemia
Research Fund Centre for Clinical Epidemiology in Leeds
University via a network of locally based data clerks. The
geographical area of case collection covers approximately
half of England and Wales (Figure 1) and notifications of
cases with a residential address within the prescribed area are
accepted. Diagnostic criteria for case registration has been
previously defined (LRF, 1987). In this paper the Rye
classification of HD is used to subdivide the disease
categories as follows: nodular sclerosing (HDNS), lym-
phocyte depleted (HDLD), lymphocyte predominant
(HDLP), mixed cellularity (HDMC) and not otherwise
specified (HDNOS). No cases are registered on clinical
grounds or from a death certificate without accompanying
histology. As a minimum all cases are reviewed by two
pathologists and most cases are incorporated into 'panel'
schemes using cell surface markers as well as an opinion
based on light microscopy. The current paper analyses cases
diagnosed between 1 January 1984 and 31 December 1986.
Ascertainment of cases is optimised by cross-checking with
data from other sources, including cancer registries, local
listings and the United Kingdom Childhood Cancer Study
Group (UKCCSG) registrations at the childhood cancer
research group in Oxford. A detailed appraisal of a cross-
check with three regional cancer registries for 1986 DCS
cases has been completed (Alexander et al., 1989a).
The study areas based on health regions and districts are
shown in Figure I and detail the DCS areas for each year of
collection. The total population taken from the 1981 census
varied according to geographical size but averaged 8 million
males and 8 million females. All cases were assigned to
administrative districts and electoral wards on the basis of
their full postal address at diagnosis.
Computerisation/validation ofdata
Registration forms designed specifically for the DCS are used
both for notification purposes and as data entry forms for
the computer (VAX 8200 series). Validation programs per-
form rigorous checks of datatype, format and data items at
input. Translation of input codes, data calculation and
informational messages maintain dialogue with the data entry
clerk and further reduce input and coding errors. In order to
avoid duplicate registrations additional logical checks are
performed on name, date of birth, address and post code. All
potential duplicates matching on these variables with any
individual on the data base are manually checked.
A current version of the central postcode directory is used
to confirm postcode validity and assign a map-reference and
small area statistics (SAS) codes 'frozen' to 1981 boundaries.
This is taken as the address at diagnosis.
Population figures stratified by sex and 5-year age groups
at county, district and ward level are taken from 1981 census
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Figure 1 Leukaemia research fund data collection study areas.
data held at the University of Manchester Regional Comput-
ing Centre.
Statistical methods
Incidence rates are expressed as rates per 105 person years
and are computed by direct standardisation using the follow-
ing age strata: 0-4, 5-14, 15-24, 25-34, 35-44, 45-54,
55-64, 65-74, and 75-84. Expected numbers are calculated
using the same age strata and 'LRF standard age-specific
rates'. These are age-specific incidence rates for 1984-86 for
the areas included in the cross-checking procedure (Alex-
ander et al., 1989a) for which optimal and uniform ascertain-
ment is assumed.
If age-specific risk of disease is the same in each area unit
and the risks for different individuals are independent then
the appropriate statistical model for the observed incidence is
the Poisson distribution with the expected incidence as mean.
This is described as a 'uniform distribution'. Observed and
expected incidence can be compared for each area unit. This
process involves a large number of statistical tests; the P
values should therefore be interpreted with caution and are
referred to as 'nominal P values'. Global testing of
differences of O/E ratios by area unit are also based on the
Poisson distribution; the method is that of Poisson regression
(Frome, 1983), using GENSTAT. It should be noted that an
explicit comparison was made of OIE ratios with E cal-
culated as above (i.e. over age-strata) and with E calculated
using age and sex stratification. There was no evidence of
differences which could alter the conclusions of any analyses.
This justified our choice of use of age-standardisation alone.
Poisson regression has also been used to test for between-
district, within-county variation.
For the investigation ofa smaller scale heterogeneity we have
applied a goodness-of-fit test ofa mixture ofPoisson distribu-
tions:
oi0 P (E)
where Oi is the observed number and E, the expected number of
cases in the ith ward 1 i<3272. We have compared the
observed andexpected numbers ofwardswith nominal Pvalues
<0.05 and <0.01 respectively. Thisisrelated totheapproach of
Gardner and Winter (1984) and is described in more detail in
Appendix 2.
Analyses
Data from the study can be analysed using a variety of
diagnostic, age and residential criteria. The present paper
provides results at four geographical levels: (i) DCS area as a
whole; (ii) administrative county; (iii) administrative district;
(iv) electoral ward. For HD at levels i and ii a range of
incidence rates and distributions by age, sex and subtype are
presented. The expected numbers of cases are calculated
using the DCS 'standard area', which comprises three
regions: Yorkshire, Trent and South West. For these areas
annual cross-checks with regional cancer registries are per-
formed and ascertainment is considered optimal (Alexander
et al., 1989a). For iii and iv the fit of the Poisson distribution
to area incidence data has been examined. Where appropri-
ate, analyses have been performed separately for the age
groups 0-34 and 35-84.
Results
Descriptive data
For the DCS (1984-86, ages 0-84), 9,268 registrations of
leukaemia, lymphoma and related conditions gave an age
standardised rate of 27.42 per 105 person years. HD cases
comprised 8.3% of the total number of DCS cases registered
in the standard area giving a standardised incidence of 2.36
per 105 person years. The male predominance of HD cases
(sex ratio male:female = 1.5) reflects the overall pattern of
registrations for the range of haematological disease. The age
and sex distribution (Figure 2) illustrates the higher propor-
tion of males occurring particularly in the first mode of the
distribution. Age-specific rates are given by 5 or 10-year age
bands in Table I; the differences in age pattern by sex are
statistically significant (P<0.01). The low rate in the under
4-year-olds is followed by a steady rise to a peak incidence in
the 15-34-year-olds. The relative proportion of the HD
contribution to the totality of the lymphomas is highest in
childhood (0-14 years) at 39%, decreasing to 26% at ages
15-64 and 5% in the 65-84-year-olds.
Examination of Rye histological types showed that 10% of
HD cases remained unclassified (HDNOS). The most com-
mon subtype was HDNS comprising 51% with HDMC cont-
ributing 24% of cases. The rarest subgroups were HDLP
(10%) and HDLD (5%). The distribution of the histological
subtypes varies considerably by age, as shown by the age
specific rates in Table II and illustrated in Figure 3. The most
striking feature is the peak for HDNS in the 15-35 age
group. Closer examination of these cases shows a female
excess in the 15-24 age band where the rate for males is 2.0
per 105 person years and for females is 2.4 per 105 person
years. No other subtype exhibits a female predominance for
any age group. Incidence for HDMC appears to rise steadily
with age from young childhood in contrast to HDLD which









Figure 2 Distribution of Hodgkin's disease by age and sex.944 P.A. McKINNEY et al.
Table I LRF data collection survey: age specific rates for Hodgkin's
disease by sex for 1984-86 cases
Male Female Pooled Age group
(Years) Obs Rate Obs Rate Obs Rate
0-4 4 0.4 0 0.0 4 0.2
5-14 20 0.8 6 0.3 26 0.5
15-24 88 3.4 80 3.2 168 3.3
25-34 96 4.1 56 2.4 152 3.3
35-44 77 3.8 43 2.2 120 3.0
45-54 66 3.6 23 1.2 89 2.4
55-64 54 3.0 39 2.0 94 2.5
65-74 44 3.2 34 1.9 78 2.5
75-84 19 3.3 22 2.1 41 2.6
All ages 468 2.9a 303 1.8a 772 2.4a
Obs, observed numbers; Rate, age specific rate per 100,000 per year.
aAge standardised rate to England and Wales 1981 population.
and the unclassified HDNOS the age related pattern
fluctuates with no obvious features apart from the decrease
of HDNOS in the 45-55 age group.
Geographical distribution
At administrative county level age standardised incidence
rates are given for each DCS county for two age groups:
0-84 and 0-34 (Table III). Nominal P values are also
shown. Somerset was the only county where observed
numbers were in a 'significant' excess over expected numbers
of HD cases for 0-84-year-olds. In view of our subsequent
analyses it is of interest that the Somerset rates for the age
group 0-34 are entirely unexceptional (O = 11, E = 11.05)
but the subsequent excess (O= 24, E = 14.7) appears
throughout the age range. The only Rye type to show an
excess for Somerset is HDMC (16 observed, 6.3 expected).
Incidence for cases registered between 1 January 1987 and 30
June 1988 is shown. These data are verified but necessarily
incomplete because of delayed registrations and are presented
for informal use only. However, Poisson regression analysis
failed to find evidence of significant differences in the O/E
ratio for different counties.
Examination of all disease subgroups within the DCS
showed HD and chronic myeloid leukaemia were the only
conditions where standard registration ratios (SRRs) did not
differ significantly between counties. The numbers of cases of
HD are comparable to those of high-grade non-Hodgkin's
lymphoma and acute myeloid leukaemia and considerably
more than those of acute lymphoblastic leukaemia. This
homogeneity reflects homogeneity of the SRRs rather than
lack of statistical power.
Administrative districts are intermediate in geographical
and population sizes between counties and electoral wards.
The lack of SRR variation at county level is reflected in the
district analysis for HD where the Poisson regression analysis
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Figure 3 Age-specific rates for Hodgkin's disease by subtype.
county analysis in the global x2 statistics for between-district,
within-county variation (147.2 and 137.7 for ages 0-84 and
0-34 respectively, both on 125 d.f.). Some districts do show
an excess with a nominal P <0.05; these are illustrated in
Figure 4. Ipswich (SASCODE 43QT) has an HD excess for
both age groups (0-34, 0-84 years). Erewash (18FQ), Bos-
ton (33MS), Nottingham (38PM) and Sedgemoor (41QC)
exhibit significant excesses only for all ages (0-84 years)
while Copeland (17FH), Bournemouth (20GG), East Lindsey
(33MT) and York (37PE) have significantly greater number
of cases only in young people (0-34 years) The Sedgemoor
excess (12 observed, 6.2 expected) contributes to that in the
entirety of Somerset (see Table III).
Small scale analysis
The larger scale geographical analyses showed no significant
differences between incidence rates in different counties or
districts. On this large scale the spatial pattern of incidence
was found to be approximately uniform. However, at the
electoral ward level there were variations.
Table IV shows the results testing the fit of the Poisson
distribution at ward level for HD and for HDNS. In HD the
results suggest a lack of fit of the Poisson distribution, and
thus a non-uniform pattern of incidence at electoral ward
level, in people aged 0-34 years. For HDNS, no significant
differences in ward incidence rates (Table IV) were evident
Table II LRFdata collection survey: agespecific rates for Hodgkin'sdiseasehistological subtypes:
sexes pooled
Hodgkin's disease: Rye subtype
HDLP HDMC HDNS HDLD HDNOS
Age group
(years) Obs Rate Obs Rate Obs Rate Obs Rate Obs Rate
0-4 0 0.0 1 0.1 2 0.1 0 0.0 1 0.1
5-14 5 0.1 5 0.1 16 0.3 0 0.0 0 0.0
15-24 17 0.3 27 0.5 112 2.2 2 0.0 10 0.2
25-34 8 0.2 30 0.6 99 2.1 2 0.0 13 0.3
35-44 14 0.4 28 0.7 57 1.4 2 0.1 19 0.5
45-54 7 0.2 29 0.8 42 1.1 7 0.2 4 0.1
55-64 14 0.4 30 0.8 30 0.8 7 0.2 13 0.3
65-74 4 0.1 21 0.7 29 0.9 12 0.4 12 0.4
75-84 4 0.2 15 0.9 9 0.6 7 0.4 6 0.4
All ages 73 0.23a 186 0.56a 396 1.20a 39 0.lla 78 0.24a
Obs, observednumberofcases; Rate, agespecific rateper 100,000peryear.aAgestandardised rate







IUK LEUKAEMIA LYMPHOMA REGISTRY 945
Table III Leukaemia Research Fund data collection survey: age standardised incidence rates of Hodgkin's
disease by county
0-34 years: 1984-86 0-84 years: 1984-86 0-84 years
Pooled sexes Pooled sexes 1987-88a
Nom Nom
Area name Rate Obs Exp SRR P Rate Obs Exp SRR P Rate Obs
South Yorkshire 1.4 27 41.7 64.7 0.01 1.8 69 90.8 76.0 0.01 0.9 18
West Yorkshire 1.5 76 65.6 115.8 0.11 2.4 140 140.7 99.5 0.50 1.7 55
Avon (part) 2.7 32 25.2 127.1 0.11 2.3 54 55.0 98.2 0.49 1.8 21
Cornwall 1.6 9 12.1 74.3 0.23 1.6 20 29.3 68.3 0.05 0.8 5
Cumbria 2.1 14 14.6 95.9 0.51 2.6 36 33.1 108.7 0.33 2.1 15
Derbyshire (part) 2.0 26 27.5 94.6 0.44 2.6 67 61.3 109.3 0.25 1.4 16
Devon 1.9 24 27.4 87.7 0.30 2.4 69 65.4 105.5 0.34 1.7 23
Dorset 3.2 16 10.8 147.9 0.08 2.5 27 27.2 99.2 0.53 1.2 9
Gloucestershire 1.8 13 15.5 83.8 0.32 2.3 33 34.6 95.4 0.44 2.5 18
Humberside 2.2 28 27.3 102.7 0.47 2.4 59 58.8 100.4 0.51 2.4 30
Lancashire 1.7 22 28.0 78.5 0.15 2.1 56 63.3 88.5 0.20 2.3 46
Leicestershire 1.9 25 27.9 89.7 0.34 2.3 56 58.4 95.9 0.41 1.1 14
Lincolnshire 3.0 24 17.0 141.3 0.06 2.9 47 38.0 123.6 0.09 1.3 18
North Yorkshire 3.0 28 20.2 138.7 0.06 2.8 53 46.1 115.0 0.17 1.9 19
Nottinghamshire 1.8 27 31.9 84.7 0.22 2.4 70 68.5 102.2 0.45 1.7 25
Somerset (part) 2.1 11 11.1 99.5 0.57 3.2 35 25.8 135.8 0.05 2.9 16
Suffolk (part) 2.5 11 9.4 117.7 0.34 2.6 23 21.0 109.8 0.36 3.2 14
Dyfed 2.5 11 9.6 115.1 0.36 2.1 20 22.6 88.4 0.34 1.5 7
Gwent 1.5 10 13.9 72.1 0.19 2.0 25 30.5 81.9 0.18 1.9 12
Mid Glamorgan 1.6 13 17.2 75.7 0.19 1.7 26 37.2 69.9 0.04 1.8 14
South Glamorgan 1.9 11 12.5 88.1 0.41 2.1 24 26.5 90.6 0.36 1.3 7
West Glamorgan 1.3 7 11.3 62.1 0.13 1.3 14 25.6 54.8 0.10 1.3 7
Rate, per I05person years; Obs, observed numbers; Exp, expected numbers; SRR, standard registration ratio
= OIE x 100; Nom, nominal; a1 January 1987 to 30 June 1988.
Figure 4 Districts with Hodgkin's disease excesses.
and the data were consistent with the Poisson distribution.
Since the denominator data are from the 1981 census and
not directly applicable to 1984-86 it was appropriate to ask
whether the ward heterogeneity of HD in young people was
an artefact of population changes. Therefore, one of use
(F.E.A.) telephoned the appropriate district or county plann-
ing authority for each of the 18 wards quoted in Table IV. In
every case information was requested on substantial popula-
tion increases in any ward in the specific district since the
1981 census. For 11 districts representing 12 of the wards
population estimates were available at some point in the
period 1984-88. In these districts 22 wards were thought to
have had substantial population increases; of these only one
was included in our category of high-risk wards (one ward in
South Lakeland which had experienced a population increase
Table IV Electoral wards with significant excesses of Hodgkin's
disease
Hodgkin's disease
Hodgkin's disease nodular sclerosing
Ward excesses Ages (years) Ages (years)
significant at 1%W 0-84 0-34 35-84 0-84 0-34 35-84
Number ofwards
Observed I 1 18 6 10 12 5
Expected 13.4 9.7 10.9 10.25 7.8 5.7
x2on 1 d.f. 0.43 7.1b - - 2.6
Total number of wards 3,292. 'Numbers significant at the 5% level
were alsocomputed and observedfigures were alwaysclose toexpected.
bStatistically significant at the 1% level.
of 11%, the eighth highest in the district). For two further
wards in two districts major boundary changes or the neces-
sity of aggregating parish data limited the comparison to the
individual wards; in each case the population had declined
slightly. Districts in Lincolnshire were only able to provide
lists of parishes with high growth rates (2-2.4% per annum).
Two 'high-risk' wards were in Lincolnshire; case addresses
were checked against the list of parishes and the two cases in
one ward both lay in one of the 27/28 parishes with high
growth rate. Finally, two of the 18 wards were in Mid
Glamorgan, for which intercensal population data at ward or
parish level was unavailable. Overall our conclusion is that
these results are unlikely to be artefacts.
Discussion
The specialist registry of haematopoetic malignancies and
related conditions held at the Leukaemia Research Fund
Centre for clinical epidemiology has a number of unique
features. Direct notifications from treating clinicians ensure
rapid notification and good diagnostic definition. The data
can be analysed using modern classifications of disease and
sophisticated computer programs to validate incoming in-
formation to a high degree of reliability. These factors com-
bine to provide an exceptional data base for this particular
range of diseases.
In order to maximise case ascertainment, cross-checking of
data with a variety of sources is particularly important. The
DCS complete annual exchanges of case listings with three946 P.A. McKINNEY et al.
large regional cancer registries: Yorkshire, Trent and South
West (Alexander et al., 1989a). Consistent data exchange
over a 3-year period was considered to pr-duce optimal
ascertainment for these regions and therefore an appropriate
area on which to calculate incidence statistics.
The DCS age standardised incidence rate for HD (2.4 per
105 person years) is slightly lower than in the USA (3.0 per
105 person years) (Glaser, 1987) but equivalent to the latest
available UK figures (males 2.8 per 105 person years, females
2.0 per 105 person years) (OPCS, 1988). The classic bi-modal
age-incidence curve for HD, first described by MacMahon
(1966), is not fully mirrored in our results, which only concur
with the peak found in young adults. In an international
context this first rise in incidence typifies the characteristic
pattern for 'well-developed countries' (Correa & O'Conor,
1971). Overall our UK pattern fails to demonstrate a
renewed rise in incidence in the over 45-year-olds, as shown
by other UK data for the years 1979-82 (Muir et al., 1987).
An explanation for these differences is not immediately ap-
parent but may relate to the DCS practise of only registering
histopathologically confirmed disease. The cross-check of
DCS and cancer registry data (Alexander et al., 1989a) did
not report diagnostic disagreement and indeed only registry
diagnoses from the South West were mounted on the LRF
computer. We have subsequently examined the reports of
HD from the South West registry for 1986; for ages 0-34, of
33 registry reports 28 were considered valid registrations by
the LRF and the only diagnositc difference was one case with
different HD subtype. For the next age group (35-49), 16
registry reports contained 15 valid LRF registrations with
again one disagreement over HD subtyping. However, in the
older cases 21 valid registrations from the 23 registry reports
showed considerable diagnostic error; three of these registra-
tions were for another condition and a further two for a
different HD subtype. Thus from 23 reports the LRF only
confirmed 18 (78%) as valid HD registrations. These figures
suggest that diagnostic differences applying primarily to older
cases may explain the unexpected LRF age-incidence curve.
In addition some systematic differences may exist in the
diagnosis of HD between the two time periods of ascertain-
ment. For example, since 1984 the use ofcell-surface markers
may have influenced diagnostic accuracy.
Few descriptive data are available on HD incidence by
histological subtype. Our observation for the UK of HDNS
accounting for the peak incidence in young people aged 14-35
years reflects that found in other western populations (Glaser,
1986). Inadditionourdatasupportsthepreviously notedfemale
excess within this group (Glaser, 1986).
For children aged 0-14 years the DCS and the national
childhood cancer registry rates for HD (Draper et al., 1982)
both illustrate the relative rarity of HD in childhood. The sex
distribution ofhistological subtypes in this age group has been
reported toexhibit an excessofHDNS infemales(Stiller, 1985).
Our data for 0- 14-year-olds contained a higher proportion of
subtyped disease and did not exhibit this feature. However, for
the next older age group (15-24 years) the DCS did reveal a
female predominance for HDNS.
HD displays geographical variation on a worldwide scale
with the age distribution and histological subtype presenting a
different picture between developed and under-developed coun-
tries. Increasing deprivation seems to correspond with earlier
presentation and more aggressive subtypes. For youngpeoplein
African countries HDMC predominates (Levy, 1988), in con-
trast to the HDNS of westernised countries. A direct com-
parison of Chinese and North American data recently
confirmed this pattern (Harrington et al., 1987), adding weight
to the growing body of evidence that higher socio-economic
status is linked to HDNS.
Because of its recent origin the DCS is as yet unable to
evaluate temporal trends and test the observations of an
increasing incidence in either HD overall (Barnes et al., 1986),
HD in youngpeople (Van Hoffet al., 1988) or more specifically
for women (Glaser, 1987). However, the absence of a second
age-specific mode in our relatively recent data set may reflect a
decreasing incidence in older adults seenin theUSA and present
for all subtypes (Glaser, 1986).
Although variation in incidence and subtypes of HD is
documented on an international level (Muir et al., 1987) little
attention has been paid to comparisons of distribution on a
smaller geographical scale. A study ofvariation in 10 regions of
the United States showed significant variation(Glaser, 1987), in
contrast to our results where distribution on this scale was
homogeneous. At the higher resolution ofdistricts a Yorkshire
study showed individual districts with significantly excessive
rates (Barnes et al., 1987a) but no global test of heterogeneity
was applied. Our data show some individual excesses but no
overall significant variation at district level; a result confirmed
by Scottish data (D. Clayton, personal communication).
A striking feature of the results presented here is the
obscuring of localised geographical aggregation which would
occur if large areas alone were examined. We confirm a
non-random HD distribution at ward level first reported for
Yorkshire for diagnoses 1974-82 (Barnes et al., 1987b) and
confirmed by Scottish data (J. Urqhart, personal communica-
tion).
Certain methodological problemscommon to spatial descrip-
tive epidemiology are present with this study. UK censuses
provide population denominators and do not therefore exactly
reflect thepopulationat riskinanyoneoftheyearsinvestigated.
This applies to all the analyses used here and because ofthis we
have chosen to use age-standardisation with relatively broad
strata. Future plans include incorporation of demographic
modelling of the age-sex structure of the population in
individual years, which is particularly appropriate for diseases
such as ALL and HD which show an early peak incidence.
In summary, the analysis of a high quality data set using
recently accrued cases have revealed some novel observations.
The absence ofany obvious bi-modality in agedistribution may
be the forerunner of distributions from other countries for
which such recent data remain to be published. The striking
early adult age peak accounted for by HDNS confirms other
descriptive data for well developed countries. However, no
previouswork hasdocumented thegeographical distribution of
HDat varying levels and it is ofinterest that the disease appears
in ahomogeneous pattern on a large scalebutsmall areas reveal
significant heterogeneity. Examination of these data for
evidence ofclustering is subsequently described (Alexander et
al., 1989b).
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The Leukaemia Research Fund Data Collection Survey group com-
prises about 400 consultant haematologists and histopathologists
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shire), Dr R.M. Hutchinson and Professor I. Lauder (Leicester), Dr
J.D. Davies (Bristol), Dr A.G. Prentice (Plymouth), Dr M. Philips
and Dr S. Johnson (Taunton), Dr J.A. Whittaker and Dr J. Gough
(Cardiff), Dr S. Ismail (Swansea), Dr D. Gorst (Lancashire and
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Appendix 2
x2goodness-of-fit test ofPoisson distributions
Under the null hypotheses of equal age-specific risk in all areas and
independence of cases the observed number of cases in the ith ward
(0,) has Poisson distribution with mean equal to the expected
number (Ei).
If all wards have equal values of Ei then the usual x2 goodness of
fit test involves computing observed (0) and expected (E) numbers of
wards with observed incidence in appropriate strata. These strata are
normally classified in terms of observed case counts; however, for
equal Ei, this is equivalent to classification by Oi/Ei ratios or by P
values. Once the Ei are allowed to differ it is necessary to select the
criteria. Case counts per se are not particularly meaningful with
variable E1; however, the division of opinion between the use of
incidence ratios and P values has been ubiquitous at least since the
Black report (Black, 1984) which used both. The problem with
sparse data is that incidence ratios are unstable and lack precision,
particularly for the smallest Eis while P values depend on the value
of Ei in a complex way (because of discreteness of the Poisson
distribution) but tend to favour larger areas. For data as sparse as
these where many wards have only one or two cases, ranking by
incidence ratio is particularly inappropriate since for each value of 0
it corresponds to ranking by E (i.e. by population). Therefore we
have chosen to classify high-risk wards by P values.
Because of the discreteness of the Poisson distribution expected
counts of wards with P<O.O1 have been computed by summing the
exact probabilities.
Pe,,= min [pr (0i > n): pr (Oi > n) <0.01]
n>1
That the expected number quoted in Table IV is considerably less
than 1% of 3,292 illustrates the extent to which Pex <0.01 for data
with such small values of Ei.
This approach is similar to that of Gardner and Winter (Gardner
& Winter, 1984; Black, 1984).
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